Drug Trial Radar · NCT05044962
Kuwa Free! - Live Free!
Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Nov 26, 2021
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- University of Alabama at BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Moi Teaching and Referral Hospital; Indiana University; University of Nebraska; National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Sep 16, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 15 years, up to 24 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study investigators are conducting foundational pharmacokinetic (PK) and qualitative studies, among 15-24 years old (inclusive) adolescent girls and young women living with HIV (AGYWLHIV) already on oral antiretroviral therapy (ART) and virally suppressed, leading up to a hybrid type I effectiveness-implementation trial randomizing individual AGYWLHIV to receive long-acting (LA) injectable cabotegravir/rilpivirine vs. standard of care within one of Kenya's largest HIV treatment programs. The PK and qualitative studies will investigate potential issues arising from co-delivery and guide delivery of the effectiveness-implementation trial. The PK and qualitative studies will largely be conducted with a sentinel cohort of AGYWLHIV. Learning from this early LA ART use, the investigators will refine the procedures in the LA ART hybrid trial.
Conditions
- HIV Infections
- Contraception
- Drug-drug Interaction
Interventions
Cabotegravir/ RilpivirineDrug
For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin). For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine) CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709
Etonogestrel (ETG) implantDrug
Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm
Intramuscular depo-medroxyprogesterone acetate (IM DMPA)Drug
DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide
LevonorgestrelDrug
Contraceptive estrogen implants are thin rods inserted under the skin of a woman's arm
NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimensDrug
ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hormone concentrations with cabotegravir/rilpivirine use (Aim 1a)Time frame: 12 or 24 weeks after DMPA or implant initiation, respectively
- Number of participants with HIV viral suppression (Aim 2a)Time frame: 48 weeks after study enrollment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Academic Model Providing Access to Healthcare (AMPATH) Moi Teaching And Referral Hospital (MTRH)
Eldoret, Kenya, Kenya · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.